A. van Drogen

Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiency

Patrick G. A. Pedrioli, C. Howald, G. Rätsch, 2022, Nature Metabolism.

Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma

J. Tchinda, B. Snijder, S. Goetze, 2023, Nature Cancer.

Targeting tumour-intrinsic neural vulnerabilities of glioblastoma

B. Snijder, S. Goetze, B. Wollscheid, 2023, bioRxiv.

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology

Vipin T. Sreedharan, Nora C. Toussaint, Christian P. Kunze, 2021, Laboratory Investigation.

ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma.

Vipin T. Sreedharan, Nora C. Toussaint, Christian P. Kunze, 2023, Cancer research.

Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis

B. Snijder, S. Goetze, R. Skoda, 2023, Nature communications.